title: [Methylphenidate. Therapy option for adults with ADHD and comorbid substance use disorder?].
abstract: Attention-deficit/hyperactivity disorder (ADHD) in adults is often associated with a comorbid substance use disorder (SUD). To date, no treatment algorithms are available. The question of whether the administration of methylphenidate (MPH) is justified in the treatment of adult patients with ADHD and comorbid SUD still remains unclear. While animal studies indicate an addictive potential of intravenous application of the drug, controlled oral treatment with MPH does not seem to carry the potential for abuse in humans. It remains controversial whether MPH treatment of ADHD during childhood protects against the development of SUD during adulthood. Although data remain inconsistent, a small number of studies and our own clinical observations of ADHD patients with SUD treated with MPH support a reduction not only of ADHD-related symptoms, but also of craving and substance abuse. The treatment of the adult ADHD with comorbid SUD with MPH should be conducted after a risk-benefit assessment, taking into consideration the abused substances, the motivation to abstinence and the quality of the physician-patient relationship; it should be evaluated critically, monitored closely and accompanied by treatment of the SUD and specific psychotherapy/psychoeducation.
authors.affiliation: Klinik für Abhängiges Verhalten und Suchtmedizin, Zentralinstitut für Seelische Gesundheit Mannheim, Universität Heidelberg, J5, 68159, Mannheim. Georgios.Paslakis@zi-mannheim.de
authors.forename: G
authors.initials: G
authors.lastname: Paslakis
authors.forename: F
authors.initials: F
authors.lastname: Kiefer
authors.forename: A
authors.initials: A
authors.lastname: Diehl
authors.forename: B
authors.initials: B
authors.lastname: Alm
authors.forename: E
authors.initials: E
authors.lastname: Sobanski
mesh_terms: D000328:Adult; D019969:Amphetamine-Related Disorders / Q000209:etiology* / Q000517:prevention & control*; D001289:Attention Deficit Disorder with Hyperactivity / Q000150:complications* / Q000188:drug therapy*; D000697:Central Nervous System Stimulants / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D008774:Methylphenidate / Q000008:administration & dosage* / Q000009:adverse effects*
chemical_list: D000697:Central Nervous System Stimulants; D008774:Methylphenidate